Elidel Labeling (Clarification)
This article was originally published in The Pink Sheet Daily
Executive Summary
An Oct. 18 1story in "The Pink Sheet" DAILY on declining sales for Novartis' eczema treatment Elidel (pimecrolimus) did not describe with sufficient clarity the status of discussions between the firm and FDA on labeling changes